Universität zu Köln

Langerbeins, Petra (2022). Cardiotoxicity in patients treated with acalabrutinib. Blood, 140 (20). S. 2096 - 2098. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

In this issue of Blood, Bhat et al systematically evaluated the rate of incident symptomatic ventricular arrhythmias (VAs) in a large case series of patients treated with acalabrutinib.1 Although the observed cardiotoxic adverse events in nearly 3% of patients treated with acalabrutinib was lower than that reported in patients treated with ibrutinib, the percentage was eightfold higher than that in similar untreated control patients. These data indicate that VAs may be a class-specific effect of Bruton tyrosine kinase inhibitors (BTKi's).

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Langerbeins, Petra UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-656910
DOI:	10.1182/blood.2022017791
Journal or Publication Title:	Blood
Volume:	140
Number:	20
Page Range:	S. 2096 - 2098
Date:	2022
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1528-0020
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language VENTRICULAR-ARRHYTHMIAS Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/65691